Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryo-Cell International, Inc. (CCEL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a NYSE American–listed company engaged in cellular processing, cryogenic storage, and cord blood banking, Cryo-Cell uses its SEC filings to report on financial performance, governance, financing arrangements, and material events.
Investors can review annual reports on Form 10-K for a comprehensive discussion of the company’s business, including its private and public cord blood banking operations, the role of PrepaCyte-CB processing technology, the ExtraVault biostorage offering, and the license agreement with Duke University. Quarterly reports on Form 10-Q provide interim financial data, segment revenue details such as processing and storage fees, public banking revenue, and product revenue, as well as updates on research and development spending and other operating items.
Current reports on Form 8-K document specific material events. Recent examples include disclosures about decisions to declare or not declare quarterly cash dividends, amendments to the company’s Credit Agreement with Susser Bank, and the setting of the annual meeting date and record date. These filings also describe changes to revolving credit commitments, maturity dates, and the addition of subsidiaries such as Celle Corp. as guarantors, which are relevant for understanding Cryo-Cell’s capital structure and liquidity.
The definitive proxy statement on Schedule DEF 14A outlines board composition, proposals for director elections, auditor ratification, and advisory votes on executive compensation, as well as stockholder voting procedures. Form 4 and related insider transaction reports, when available, can be used to track trading activity by directors and officers.
Stock Titan’s AI tools summarize key points from 10-K, 10-Q, 8-K, DEF 14A, and other filings, helping users quickly identify disclosures on dividends, credit facilities, governance matters, and strategic initiatives without reading every page of the original documents.
Cryo-Cell International (CCEL) filed a Form 4 reporting a director equity award. On 10/21/2025, director Daniel Mizrahi received a grant of stock options to purchase 5,300 shares at $4.35 per share, expiring on 10/21/2035. The options vest at a rate of 1/12 per month commencing on 10/21/2025.
Following the reported transactions, the reporting person directly beneficially owned 30,634 shares of common stock. The filing also lists prior option grants of 5,300 shares each dated 10/20/2021, 10/03/2022, 10/10/2023, and 10/29/2024 with exercise prices of $12.63, $6.50, $4.90, and $5.82, respectively.
Cryo-Cell International (CCEL) director reported a new stock option grant. On 10/21/2025, the director received options for 5,300 shares at an exercise price of $4.35, exercisable on 10/21/2025 and expiring on 10/21/2035. Following the reported transactions, the director directly beneficially owned 57,901 shares of common stock. The filing also lists multiple prior stock option awards with various exercise prices and maturities.
Cryo-Cell International (CCEL) filed its quarterly report, showing stable operations with softer topline. Revenue for the quarter ended August 31, 2025 was $7.83 million versus $8.07 million a year ago, as public banking and product sales remained small. Operating income improved to $1.90 million from $1.39 million on lower cost of sales and SG&A. Net income was $0.75 million ($0.09 diluted EPS) compared with $1.05 million ($0.13) last year.
For the nine months, revenue was $23.72 million versus $23.96 million; net income was $1.39 million ($0.17 diluted EPS) versus $2.26 million ($0.27). Interest expense weighed on results at $0.54 million in the quarter and $1.58 million year-to-date.
Deferred revenue tied to long-term storage contracts rose to $59.58 million ($9.74 million current), supporting future revenue recognition. Cash was $265,207 with $2.96 million in marketable securities. The company reported a stockholders’ deficit of $14.83 million driven by deferred revenue accounting and treasury stock. Debt included a $3.20 million line of credit and $8.39 million term note. As of October 15, 2025, 8,055,150 common shares were outstanding.
The proxy discloses governance and shareholder procedural details for Cryo-Cell International, Inc. It states the Audit Committee charter defines the committees duties, membership rules and relationship with independent auditors and management but does not set director nomination procedures. The document lists exact stockholder nomination and proposal submission requirements, including identity, holdings, arrangements, nominee consents and intent to solicit or appear at the meeting. Beneficial ownership disclosures include Adam Fleishman reporting 279,000 shares held by his trust and 230,000 shares personally, and a Patent and Technology License with Duke University that issued 409,734 shares upon execution. Detailed ownership allocations are provided for David Portnoy and Mark Portnoy (including 401(k), IRA, individual holdings, related-entity holdings and numerous option pools). Multiple stock option vesting schedules and executive post-termination benefits for disability and death (including two times base salary and continued insurance coverage) plus non-compete and non-solicit restrictions are described.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings
Insider purchases by Cryo-Cell International director and 10% owner David Portnoy are reported across September 8-10, 2025. The Form 4 shows multiple open-market purchases of Common Stock at prices between $4.30 and $4.49, including a 5,271-share purchase at a weighted average $4.31 on 09/08/2025 and a series of purchases on 09/09-09/10/2025. The listed transactions total 42,900 shares acquired during the reported dates, and the filing details existing indirect holdings and option positions, including several outstanding stock options covering 529,879 shares in the aggregate. The report is signed by David Portnoy.
Cryo-Cell International, Inc. has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025. The company set September 15, 2025 as the record date, which means only stockholders of record on that date will be entitled to receive notice of and vote at the meeting.
Stockholders who want to present business or nominate directors at the Annual Meeting must deliver the required notice under the Company’s Bylaws no later than the 10th calendar day after public disclosure of the meeting date, which occurred on September 10, 2025.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, filed a Form 4 reporting insider changes on 09/02/2025. The filing discloses a disposition of 15,611 shares of common stock on that date at an effective price of $0.00. The explanation states the child reached majority and the reporting person no longer has beneficial ownership of those shares.
The filing also lists the reporting person’s existing beneficial holdings and derivative positions. Non-derivative holdings are shown across multiple accounts and entities (including direct holdings and interests through retirement accounts, family members, and affiliated entities). Reported stock options total significant positions including 280,000 options at $12.27 (expiring 12/22/2028) and multiple tranches of 50,000 options at various strike prices and expirations.
David I. Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company’s common stock and discloses outstanding stock options. Between 08/25/2025 and 08/27/2025 Portnoy purchased several lots through retirement accounts, including 4,500 shares at a weighted average $4.65, 5,000 shares at $4.65, 11,101 shares at $4.44, 7,860 shares at $4.42, 4,500 shares at a weighted $4.53, and 6,218 shares at $4.44. The Form 4 lists numerous indirect holdings (by 401k, IRA, spouse, LLCs and corporations) and multiple outstanding stock options with exercise prices ranging from $4.30 to $12.27 covering named share amounts up to 280,000 shares for the $12.27 option.
Cryo-Cell International’s Chairman, Co-CEO and 10% owner David Portnoy reported indirect open-market purchases totaling 19,301 shares of common stock. The buys, made through retirement and similar accounts on August 15, 18 and 19, 2025, were executed at weighted-average prices ranging from about $4.23 to $4.50 per share.